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ABSTRACT-A phase I trial was conducted of the vitamin A derivative
(J-all-trans-retinoic acid (vitamin A acid; TRA), delivered via a collagen
sponge and cervical cap for mild or moderate intraepithelial cervical
neoplasia. On the basis of known skin and mucosal membrane toxicity,
a concentration of 0.05% TRA in a cream-based vehicle was selected
as the starting dose and was escalated later with the use of a modified
Fibonacchi scale. The delivery device and the TRA were changed daily
for 4 days, and side effects were assessed on days 1, 2, 3, 4, 8, and 30
by clinical and colposcopic examination. Vaginal, cervical, and systemic
toxicity were evaluated in 35 patients. No dose-related systemic effects
were found; mild cervical inflammation increased in many patients at
higher doses. Unacceptably high vaginal toxicity was reached at a TRA
concentration of 0.484%. A concentration of 0.372% TRA is recom-
mended for use in phase II trials in mild and moderate cervical intraepi-
thelial neoplasia.-JNCI 1983; 71:921-925.
Whether they have been initiated by physical, chemi-
cal, or viral carcinogens, vitamin A and its natural and
synthetic derivatives (retinoids) can block the phenotypic
progression of cells to cancer (1, 2). Numerous investi-
gators have shown that retinoids inhibit cellular prolif-
eration of many transformed cells (3), an event accom-
panied by evidence of cellular differentiation or matu-
ration in many systems including murine (4) and human
melanoma (5), human neuroblastoma (6), and promye-
locyte (7) cells. Clinical responses of preneoplastic (8, 9)
and neoplastic (10, 11) skin lesions to TRA have been
reported, and we have recently detected activity of 13-
ris-RA against neoplastic lesions of squamous cell histol-
ogy (12).
Chemoprevention for certain human cancers should
be possible on the basis of data on the retinoids (1, 2)
and on many other compounds (13) in experimental
animals. A major problem with pharmacological inter-
vention for human precancerous conditions is the inevi-
table toxicity that is expected to occur with the ingestion
of almost any chemopreventive agent (14, 15). Although
a tremendous effort was committed to develop nontoxic
chemopreventive agents for human use, particularly with
regard to retinoids, it is unlikely that the design of a
completely nontoxic, tissue-selective chemopreventive
compound will be achieved. As we have discussed else-
where, an alternative approach is to develop devices
capable of selective local or regional delivery of the
chemopreventive compound (14).
We have previously tested a collagen sponge and dia-
phragm insert to deliver TRA to the cervix, but we
found an undesirable leakage of the retinoid preparation
onto the vagina and vulva (16). Other side effects were
mild, and we noted the development of early changes in
the intraepithelial necplasias. These results were suffi-
ciently encouraging, so we developed an alternative and
effective delivery device, which consists of an inert col-
lagen sponge and cervical cap and eliminates the problem
of leaking. We report here a phase I trial of TRA,
delivered via a collagen sponge serving as a drug reser-
voir fitted into a cervical cap, for mild or moderate
intraepithelial cervical neoplasia in 35 patients.
MATERIALS AND METHODS
Patient characteristics.-All patients entered into this
trial had colposcopically directed biopsies which showed
mild or moderate dysplasia. The lesion and the entire
transformation zone (squamocolumnar junction) were
completely visualized. Endocervical currettage had neg-
ative results in all patients, and the pretreatment Papan-
icolaou smear result was consistent with that of the
ectocervical biopsy. In all patients the extent of disease
was documented with colpophotographs; all had negative
vaginal cultures for Staphylococcus aureus.
TRA administration,-TRA was dissolved in a cream-
based vehicle, which contained polyethylene glycol 400,
butylated hydroxytoluene, and 55% alcohol. TRA was
incorporated into the cream under special minimal UV
lighting (Sylvania Red F96T 12-R tubes) to prevent pho-
toisomerization and decomposition. Uniformity and con-
tent of TRA was confirmed by reverse-phase high-pres-
sure liquid chromatography with the use of a previously
published assay method (17). The prepared creams were
also negative for endotoxin pyrogens according to the
ABBREVIATIONS USED: RA=retinoic acid; TRA=(J-all-tmns-retinoic
acid.
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TABLE I.-Clinical and colposcopicgrading for cervical effects
cervical vascularity was noted in 8, 12, 16, and 3 patients
2, 3, 4, and 8 days, respectively, after initiation of the
trial.
Vaginal side effects occurred at all dose le~els and
were mild in 23 patients at concentrations of
0.05-0.372% TRA. Moderate vaginal toxicity was
noted in 5 of 21 patients at TRA concentrations of
0.1167-0.372%. At an RA concentration of0.484%, all
3 patients treated developed a moderate amount. of
discharge and 1 of 3 patients developed both bleedmg
after the last application, lasting for 1 day, and severe
and prolonged vaginal burning, lasting 12 days after the
last application.
Follow-up results.-Table 4 shows a summary of the
colposcopic, Papanicolaou cytology, and tissue biopsy
changes in patients whose pretreatment and 6-month
follow-up results were available. Twenty-nine patients
were evaluated by colposcopic mapping. The extent
and/or severity of the lesion were decreased more than
50% in 23 patients. The lesion did not worsen in any of
the patients. Among the 25 patients in whom Papanico-
laou's cytology test was available, fewer dysplastic cells
TABLE 2.-Grading of vaginal toxicity
Description of toxicity Optional action(at each 24 hr)
Stop trial in that patient.
Do not escalate dose in
next patient and treat 3
more patients at this
dose before further es-
calation.
Stop trial in that patient.
Do not escalate dose in
next patient and treat 3
more patients at this
dose before further es-
calation.
Continue treatment.
Continue another 24 hr at
same concentration.
Continue another 24 hr at
same concentration.
Optional action
(at each 24 hr)
Continue treatment
Continue treatment another
24 hr at same concentration
Continue treatment another
24 hr at same concentration
Stop trial in patient. Do not
escalate dose in next pa-
tient and treat 3 more pa-
tients at this dose before
further escalation.
None
Mild burning, irritation,
itching, or discharge
not bothersome to pa-
tient (elicited from the
patient)
Moderate burning, irri-
tation' itching, or dis-
charge not bothersome
to patient (described
by the patient)
Severe (bothersome)
burning, itching, or ir-
ritation; discharge re-
quiring a pad; ery-
thema and/or increas-
ing vascularity of vagi-
nal mucosa
Burning, itching, irrita-
tion, or discharge
leading to discontin-
uation of treatment;
ulceration and/or
bleeding
Description of
symptoms
Ulceration
None
Erythema
Erythema, vascularity
2+ (moderate)
Grade of
toxicity
3+ (severe)
Grade of cer-
vical effect
o
1+ (mild)
2+ (moderate)
3+ (severe)
o
1+ (mild)
RESULTS
Side efJects.-The systemic, cervical, and vaginal to~­
icity in these patients as related to the dose of RA IS
given in table 3.
Systemic side effects were mild and not clearly related
to the RA dose. Patients demonstrated acceptable cer-
vical side effects (1+-2+) to all dose levels tested. We did
not note cervical changes by colposcopy until after 2
days of application in most cases. Mild inflammation was
the most frequent side effect in 22 patients followed by
a moderate increase in vascularity in 19 cases. Only 1 of
7 patients treated with less than ~.067% RA.experience?
cervical inflammation. Most patients expenenced cervi-
cal inflammation with increasing dose and increased
duration of treatment. Inflammations among the 35
patients were recorded 2, 3, 4, and 8 ?ays after the. start
of the trial in 10, 11, 21, and 7 patients, respectively.
Subsequent to the inflammatory changes, an increase in
Limulus amebocyte lysate method (Pyrogent; Mallinck-
rodt Inc., St. Louis, Mo.). On the basis of our prior
studies (16), and skin and mucosal side effects to TRA
previously reported by us (11, 12) and by others (10),
we selected 1 ml 0.05% TRA as the initial dose. Escala-
tion of dosage followed a modified Fibonacchi scale (see
table 3). .
Deltuer» s'Vstem.-The delivery system consisted of a
cervical cap within which a collagen sponge was inserted
(fig. 1). The cervical cap was made of the. hydrogel
Hypan (Sky Biopolymers, Princeton, N.].) which, when
in contact with wet tissue surfaces, adheres to them by a
force of differential osmotic pressures. The characteris-
tics and properties of the collagen sponge are extensively
described elsewhere (18). The sponges were made from
pure collagen isolated from bovine skin, swollen at pH
3.0, and stabilized into the physical form of a sponge
layer. Glutaraldehyde was used as a cross-linking agent
to provide high resilience and fluid-binding capacity.
The average pore size was 400 A (range 80-1,400 A!.
The sponges were cut into thin, round wafers approxI-
mately 3-4 mm thick and 7 mm in diameter.
Schedule ofTRA adnunistratum.s-e-Cnu: milliliter of fresh
retinoid preparation was applied to the sponge, and the
sponge-cervical cap device was carefully ins~r~ed by the
investigator into the vaginal vault. The posinon of the
cap around and against the cervix was documented by
clinical examination. Patients returned daily for removal
of the sponge-cap insert. One milliliter of fresh ?rug
and vehicle was applied to a new sponge, and the delivery
device was reapplied. This procedure was repeated daily
for a total of 4 days.
Evaluation of side effects.-We evaluated toxicity by
clinical examination, colposcopy, and colpophotographs
at the time of the second, third, and fourth collagen
sponge applications and 1 week and 1 month after the
initial application. Liver function tests were performed
prior to entry into study and on the 4th d.ay of th.e~apr
Our grading system for cervical and vagmal tOXICIty IS
outlined in tables 1 and 2, respectively.
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Papanicolaou's cytology test
Colposcopy
Extent and severity of lesions No. of cases
DISCUSSION
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3 patients experienced unpleasant vaginal side effects.
Since the worst vaginal toxicity occurred after the cer-
vical delivery device was removed, we presume that these
side effects represented continued leaching ofTRA from
a saturated cervix.
The evaluation of cervical intraepithelial neoplasia is
complex. Most studies in animals indicate that the reti-
noid must be available continuously for maximal preven-
tive benefit. Preliminary assessment consists of cytologic
analysis and colposcopic evaluation to provide informa-
tion on the extent of the lesion. Complete normalization
of cytologic and colposcopic findings and a negative
tissue biopsy specimen indicate the resolution of intra-
epithelial neoplasia. In this study, we did not see com-
plete resolution of preneoplastic conditions. Neverthe-
less, our pretreatment evaluations suggest that colpos-
copic and histologic improvement can be achieved in
some patients. However, a definitive statement will re-
quire extensive follow-up, and in particular, a random-
ized trial as discussed below.
Data from this study suggest that TRA delivered to
the cervix via a collagen sponge-cervical cap insert is
both feasible and well tolerated. The absence of signifi-
cant systemic side effects after 4 days of treatment sug-
gests that the development of a local "maintenance"
retreatment protocol is reasonable. A concentration of
0.484% TRA appears to be dose limiting because it
causes delayed vaginal toxicity. On the basis of these
conclusions, we plan to treat patients with moderate
intraepithelial neoplasia with a 4-day application of
0.372% TRA, then retreat for 2 days every 3 months.
These patients will be carefully monitored for systemic
effects in this long-term trial. The results from such a
trial will have important implications for the long-term
use of retinoids for preneoplasia of the cervix and for
other precancerous conditions.
3
12
7
Biopsy
Worsened
No change
Improved
Increased 0
No change 4
Decreased 25% 2
Decreased 50% 6
Decreased 75-100% 17
TABLE 4.-Changes in intraepitheliallesions 6 months
after retinoid treatment
Worsened 4
No change 12
Improved 9
Chemotherapy of cancers in humans by the reversal
of established preneoplasia is a new concept that evolved
from encouraging results in an extensive number of
laboratory and clinical studies (1-13). The present chem-
oprevention trial provides data on the side effects and
toxicity of a collagen sponge-cervical cap delivery system
for topically applied TRA to intraepithelial neoplasia of
the cervix.
Systemic side effects were mild and probably related
to the close monitoring and frequent pelvic examina-
tions, rather than to TRA, inasmuch as no dose-response
relationship was evident. In our previous study no evi-
dence of systemic absorption of retinoids could be doc-
umented by high-pressure liquid chromatographic mea-
surements (16). Cervical alterations by colposcopy were
noted in 19 of 37 patients on day 8. None of the TRA
concentrations used in this study produced unacceptable
cervical toxicity. The effects of TRA on the cervix were
mild and similar to those we have reported with the use
of a collagen sponge-diaphragm delivery system (16),
and they represent clear evidence of the effect of the
retinoid. In addition, we used tritium labeled TRA to
document uptake into the cervical tissue (Meyskens FL,
Alberts DS, Survit EA: Unpublished data).
Vaginal side effects were predominantly mild from a
dose of 0.05-0.372% TRA and consisted of increased
discharge, itching, irritation, and burning during the 4-
day application period. With a concentration of 0.372%
of TRA, moderate (2+) itching, irritation, and burning
occurred after completion of the 4-day application in
2-5 patients. With a concentration of 0.484% TRA, all
developed in 9 patients, whereas in 4 cases more dys-
plastic cells were identified. Biopsy results of involved
tissue or of an area adjacent to the worst initial lesion
(identified by colposcopy) were available from 22 pa-
tients. In the majority, (12 patients), the lesion was
unchanged. However, in 7 patients the lesion became
more benign, whereas in 3 the histology worsened.
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FIGURE I.-Collagen sponge and cervical cap delivery device. The inert collagen sponge was impregnated with 1 ml TRA and placed in the
cervical cap. The entire delivery device was placed over the cer vix and remained attached by differential osmoti c pressu re, which cr eated a
leak-proof seal. The complete setup was changed daily for a total of 4 da ys, and systemic, vaginal , and cervical to xicities were evaluated .
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